SyndicateRoom announces a string of significant funding successes across its Access EIS Fund portfolio, highlighted by the successful Series A close for biotech pioneer Antiverse in early March. This follows a series of substantial raises by Incard, Hub Box, and a landmark $60 million financing for Nivoda, collectively totalling over £70 million in new capital for the portfolio within the last six months.
The surge in funding underscores the success of the Access EIS Fund’s data-driven strategy, which focuses on co-investing alongside the UK’s most elite “super angel” investors to identify future market leaders at their earliest stages.
Latest funding highlights: Biotech, fintech, and logistics innovation
- Antiverse (3 March 2026): Cardiff-based biotech Antiverse has today secured $9.3 million (£7.3 million) in Series A funding. The company uses generative AI to design antibodies for “undruggable” disease targets. The capital will be used to advance its internal pipeline toward in vivo studies and expand its AI-driven antibody discovery platform.
- Incard (2 February 2026): Fintech platform Incard closed a £10 million Series A round to scale its “financial operating system” for the creator economy. The platform, which integrates banking and automated accounting, is using the funds for rapid geographical expansion across Europe and the US.
- Hub Box (24 November 2025): E-commerce logistics specialist Hub Box raised £6 million in a Series A round led by Puma Growth Partners. Its software enables retailers to offer local pickup points at checkout, solving the global “failed delivery” crisis for brands like Gymshark and Selfridges.
Nivoda: A $60m landmark for global jewellery supply chains
A major highlight for the portfolio was the 30 September 2025 announcement that Nivoda, the B2B marketplace for the global diamond and gemstone industry, secured a $60 million (£44.6 million) financing facility from i80 Group.
This capital is being deployed to provide embedded trade credit to Nivoda’s network of over 10,000 retailers, allowing them to purchase inventory with flexible payment terms. This landmark raise follows Nivoda’s previous $51 million Series C and represents a significant scaling of its “capital-efficient growth machine,” which has seen its share price increase by over 480% since its initial investment from the Access EIS Fund in 2020.
A legacy of high-performance growth
These recent successes join an established track record of high-growth companies within the Access EIS Fund:
- Moth Drinks: A standout from the 2020 cohort, Moth has achieved national retail dominance in the premium cocktail category, delivering a MOIC of over 10x. MOTH secured a £4.6 million investment led by transatlantic venture capital firm Beringea to accelerate growth in the US, expand their team, and boost marketing.
- PoroTech: Following a £20 million raise in late 2022, PoroTech is now mass-producing its world-first microLED micro-projectors for the AR and AI computing markets.
“The funding rounds for Antiverse, Incard, Hub Box, and Nivoda are a direct result of our data model’s ability to find quality,” says Tom Britton, Co-founder of SyndicateRoom. “By following the UK’s most successful private investors, we gain access to the deals that top-tier VCs and institutional lenders compete to lead at the Series A and C stages. We aren’t just picking companies; we are backing a proven system of expert discovery.”
For more information, please visit www.syndicateroom.com.
To learn more about the world of tax-efficient investments, be sure to check out our recent Tax-Efficient Investment Insights!
